GGrantIndex
← Leaderboards

Albert Craig Lockhart

Vanderbilt University

$3,804,812
Attributed
$8,130,950
Total exposure
9
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.4M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,130,950 · 9

By mechanism

UG1$4,774,115 · 1
K12$1,012,554 · 1
UM1$707,333 · 1
K23$620,190 · 1
R21$549,512 · 1
P50$463,348 · 1

Others in their field

Top investigators on “Research Personnel

Research focus

Research PersonnelCancer CenterMalignant NeoplasmsClinical ResearchProgramsUniversitiesCancer PatientImageEnrollmentMedicalBaseClinical TrialsInstitutionRecruitPreventionFutureCancer ControlTranslational ResearchAnticancer ResearchCancer PreventionFundingPatient PopulationAftercareOncology

Grant awards (25)

Medical University of South Carolina NCORP Community Site$1,038,731
UG1 · FY2025 · CA
Medical University of South Carolina NCORP Minority/Underserved Community Site$948,023
UG1 · FY2024 · CA
Medical University of South Carolina NCORP Minority/Underserved Community Site$993,808
UG1 · FY2023 · CA
Medical University of South Carolina NCORP Minority/Underserved Community Site$970,975
UG1 · FY2022 · CA
MUSC/HCC Paul Calabresi Clinical Oncology Career Development Program$396,181
K12 · FY2022 · CA
Medical University of South Carolina NCORP Minority/Underserved Community Site$822,578
UG1 · FY2021 · CA
MUSC/HCC Paul Calabresi Clinical Oncology Career Development Program$616,373
K12 · FY2021 · CA
Developmental Research Program$103,135
P50 · FY2020 · CA · contact PI
Developmental Research Program$96,559
P50 · FY2019 · CA · contact PI
Developmental Research Program$103,718
P50 · FY2018 · CA · contact PI
Developmental Research Program$84,023
P50 · FY2017 · CA · contact PI
Developmental Research Program$75,913
P50 · FY2016 · CA · contact PI
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$201,163
UM1 · FY2015 · CA
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer$506,170
UM1 · FY2014 · CA
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction$264,256
R21 · FY2008 · CA · contact PI
Genetic Polymorphisms Affecting Chemotherapy Disposition$122,585
K23 · FY2008 · CA · contact PI
Genetic Polymorphisms Affecting Chemotherapy Disposition$1,453
K23 · FY2008 · CA · contact PI
Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction$285,256
R21 · FY2007 · CA · contact PI
Genetic Polymorphisms Affecting Chemotherapy Disposition$124,038
K23 · FY2007 · CA · contact PI
Genetic Polymorphisms Affecting Chemotherapy Disposition$124,038
K23 · FY2006 · CA · contact PI
CORRELATION ON THE PHARMACOKINETICS AND TOXICITY OF CPT-11 WITH FUNCTIONALLY$1,258
M01 · FY2006 · RR · contact PI
RESPONSE TO PACLITAXEL RELATED TO GENITIC VARIATINS IN MDR1$1,258
M01 · FY2006 · RR · contact PI
Genetic Polymorphisms Affecting Chemotherapy Disposition$124,038
K23 · FY2005 · CA
CORRELATION ON THE PHARMACOKINETICS AND TOXICITY OF CPT-11 WITH FUNCTIONALLY$1,382
M01 · FY2005 · RR
Genetic Polymorphisms Affecting Chemotherapy Disposition$124,038
K23 · FY2004 · CA